Item 1. | |
(a) | Name of issuer:
Immunocore Holdings plc |
(b) | Address of issuer's principal executive
offices:
92 Park Drive, Milton Park, Abingdon, Oxfordshire, United Kingdom, OX14 4RY |
Item 2. | |
(a) | Name of person filing:
Bahija Jallal, Ph.D. |
(b) | Address or principal business office or, if
none, residence:
The address and principal business office of the Reporting Person is:
c/o Immunocore Holdings plc
92 Park Drive, Milton Park
Abingdon, Oxfordshire OX14 4RY
United Kingdom |
(c) | Citizenship:
United States |
(d) | Title of class of securities:
Ordinary shares, nominal value of GBP0.002 per share |
(e) | CUSIP No.:
45258D105 |
Item 3. | If this statement is filed pursuant to §§
240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: |
(a) | Broker
or dealer registered under section 15 of the Act (15 U.S.C. 78o); |
(b) | Bank
as defined in section 3(a)(6) of the Act (15 U.S.C. 78c); |
(c) | Insurance
company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c); |
(d) | Investment
company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8); |
(e) | An
investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E); |
(f) | An
employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F); |
(g) | A
parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G); |
(h) | A
savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.
1813); |
(i) | A
church plan that is excluded from the definition of an investment company under section 3(c)(14)
of the Investment Company Act of 1940 (15 U.S.C. 80a-3); |
(j) | A
non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S.
institution in accordance with § 240.13d-1(b)(1)(ii)(J), please
specify the type of institution: |
(k) | Group,
in accordance with Rule 240.13d-1(b)(1)(ii)(K). |
| |
Item 4. | Ownership |
(a) | Amount beneficially owned:
As of December 31, 2024, Dr. Jallal was the beneficial owner of 4,493,139 ordinary shares, consisting of 4,493,139 ordinary shares underlying outstanding options held by Dr. Jallal that are or will be exercisable within 60 days of December 31, 2024. |
(b) | Percent of class:
8.2%, which is based on a total of 50,032,770 ordinary shares (including ordinary shares in the form of American Depositary Shares) outstanding as of October 31, 2024, as reported by the Issuer in its Form 10-Q for the quarter ended September 30, 2024, filed with the United States Securities and Exchange Commission on November 6, 2024. % |
(c) | Number of shares as to which the person has:
|
| (i) Sole power to vote or to direct the vote:
4,493,139
|
| (ii) Shared power to vote or to direct the
vote:
0
|
| (iii) Sole power to dispose or to direct the
disposition of:
4,493,139
|
| (iv) Shared power to dispose or to direct the
disposition of:
0
|
Item 5. | Ownership of 5 Percent or Less of a Class. |
| |
Item 6. | Ownership of more than 5 Percent on Behalf of
Another Person. |
|
Not Applicable
|
Item 7. | Identification and Classification of the
Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or
Control Person. |
|
Not Applicable
|
Item 8. | Identification and Classification of Members of
the Group. |
|
Not Applicable
|
Item 9. | Notice of Dissolution of Group. |
|
Not Applicable
|